On the public citation graph
One Size Does Not Fit All: Challenging Some Dogmas and Taboos in Drug Discovery
0 signed · 72 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1007/s11095-013-1007-6openalex-snapshot
Metabolism and Disposition of Acetaminophen: Recent Advances in Relation to Hepatotoxicity and Diagnosis
inferredcites →https://doi.org/10.1016/j.bmcl.2015.06.023openalex-snapshot
Hide and seek: Identification and confirmation of small molecule protein targets
inferredcites →https://doi.org/10.1016/j.cbpa.2008.03.016openalex-snapshot
The impact of natural products upon modern drug discovery
inferredcites →https://doi.org/10.1016/j.ddtec.2004.11.007openalex-snapshot
Lead- and drug-like compounds: the rule-of-five revolution
inferredcites →https://doi.org/10.1016/j.drudis.2007.10.022openalex-snapshot
A Sorcerer's apprentice and The Rule of Five: from rule-of-thumb to commandment and beyond
inferredcites →https://doi.org/10.1016/j.drudis.2011.12.007openalex-snapshot
Drug discovery in the next decade: innovation needed ASAP
inferredcites →https://doi.org/10.1016/j.drudis.2012.05.007openalex-snapshot
Drug discovery in pharmaceutical industry: productivity challenges and trends
inferredcites →https://doi.org/10.1016/j.drudis.2013.01.008openalex-snapshot
Shifting from the single to the multitarget paradigm in drug discovery
inferredcites →https://doi.org/10.1016/j.drudis.2013.03.002openalex-snapshot
Compound promiscuity: what can we learn from current data?
inferredcites →https://doi.org/10.1016/s0169-409x(00)00129-0openalex-snapshot
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1
inferredcites →https://doi.org/10.1016/s0169-409x(96)00423-1openalex-snapshot
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
inferredcites →https://doi.org/10.1016/s1056-8719(00)00107-6openalex-snapshot
Drug-like properties and the causes of poor solubility and poor permeability
inferredcites →https://doi.org/10.1016/s1359-6446(03)02888-5openalex-snapshot
Idiosyncratic toxicity: the role of toxicophores and bioactivation
inferredcites →https://doi.org/10.1021/acs.jmedchem.5b00294openalex-snapshot
Learning from PAINful lessons
inferredcites →https://doi.org/10.1021/cr100222qopenalex-snapshot
Mechanisms of Chemical Carcinogenicity and Mutagenicity: A Review with Implications for Predictive Toxicology
inferredcites →https://doi.org/10.1021/jm5006463openalex-snapshot
Polypharmacology: Challenges and Opportunities in Drug Discovery
inferredcites →https://doi.org/10.1021/jm501402xopenalex-snapshot
Promiscuous 2-Aminothiazoles (PrATs): A Frequent Hitting Scaffold
inferredcites →https://doi.org/10.1021/jm5019093openalex-snapshot
PAINS in the Assay: Chemical Mechanisms of Assay Interference and Promiscuous Enzymatic Inhibition Observed during a Sulfhydryl-Scavenging HTS
inferredcites →https://doi.org/10.1021/jm901137jopenalex-snapshot
New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays
inferredcites →https://doi.org/10.1021/ml3002105openalex-snapshot
Four Lessons from Global Health Drug Discovery: Medicine for an Ailing Industry?
inferredcites →https://doi.org/10.1021/np200906sopenalex-snapshot
Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010
inferredcites →https://doi.org/10.1021/tx200337bopenalex-snapshot
Reactive Aldehyde Metabolites from the Anti-HIV Drug Abacavir: Amino Acid Adducts as Possible Factors in Abacavir Toxicity
inferredcites →https://doi.org/10.1021/tx700186popenalex-snapshot
Idiosyncratic Drug Reactions: Past, Present, and Future
inferredcites →https://doi.org/10.1038/513481aopenalex-snapshot
Chemistry: Chemical con artists foil drug discovery
inferredcites →https://doi.org/10.1038/bjc.2014.271openalex-snapshot
Molecular targets of aspirin and cancer prevention
inferredcites →https://doi.org/10.1038/nature03193openalex-snapshot
Navigating chemical space for biology and medicine
inferredcites →https://doi.org/10.1038/nrd1156openalex-snapshot
Drug research: myths, hype and reality
inferredcites →https://doi.org/10.1038/nrd1470openalex-snapshot
Can the pharmaceutical industry reduce attrition rates?
inferredcites →https://doi.org/10.1038/nrd1657openalex-snapshot
The evolving role of natural products in drug discovery
inferredcites →https://doi.org/10.1038/nrd2084openalex-snapshot
Case histories, magic bullets and the state of drug discovery
inferredcites →https://doi.org/10.1038/nrd2201openalex-snapshot
Drugs for bad bugs: confronting the challenges of antibacterial discovery
inferredcites →https://doi.org/10.1038/nrd3368openalex-snapshot
Impact of high-throughput screening in biomedical research
inferredcites →https://doi.org/10.1038/nrd4090openalex-snapshot
Phase II and Phase III attrition rates 2011–2012
inferredcites →https://doi.org/10.1038/nrd4510openalex-snapshot
The re-emergence of natural products for drug discovery in the genomics era
inferredcites →https://doi.org/10.1038/nrd4609openalex-snapshot
An analysis of the attrition of drug candidates from four major pharmaceutical companies
inferredcites →https://doi.org/10.1111/j.1476-5381.2010.01127.xopenalex-snapshot
Principles of early drug discovery
inferredcites →https://doi.org/10.1124/jpet.110.171751openalex-snapshot
Productivity Shortfalls in Drug Discovery: Contributions from the Preclinical Sciences?
inferredcites →https://doi.org/10.1186/1472-6904-5-3openalex-snapshot
Promiscuous drugs compared to selective drugs (promiscuity can be a virtue)
inferredcites →https://doi.org/10.12688/f1000research.5426.1openalex-snapshot
Activity artifacts in drug discovery and different facets of compound promiscuity
inferredcites →https://doi.org/10.1517/17425255.2.6.923openalex-snapshot
Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology
inferredcites →https://doi.org/10.1586/17512433.1.4.515openalex-snapshot
Toxicophores, reactive metabolites and drug safety: when is it a cause for concern?
inferredcites →https://doi.org/10.1586/ecp.12.74openalex-snapshot
Polypharmacology: drug discovery for the future
inferredcites →https://doi.org/10.2165/00002018-200023020-00001openalex-snapshot
The Value of Reporting Therapeutic Ineffectiveness as an Adverse Drug Reaction
inferredcites →https://doi.org/10.2174/092986710793348545openalex-snapshot
False Positives in the Early Stages of Drug Discovery
inferredcites →https://doi.org/10.2174/092986711796391714openalex-snapshot
Managing the Liabilities Arising from Structural Alerts: A Safe Philosophy for Medicinal Chemists
inferredcites →https://doi.org/10.2174/0929867311320130004openalex-snapshot
Polypharmacology in a Single Drug: Multitarget Drugs
inferredcites →https://doi.org/10.2174/0929867321666141112122118openalex-snapshot
Should the Incorporation of Structural Alerts be Restricted in Drug Design? An Analysis of Structure-Toxicity Trends with Aniline-Based Drugs
inferredcites →https://doi.org/10.3389/fphar.2014.00264openalex-snapshot
Phenotypic screening in the 21st century
inferredcites →https://doi.org/10.4155/fmc.11.44openalex-snapshot
Growing PAINS in Academic Drug Discovery
inferredcites →https://doi.org/10.4155/fmc.14.25openalex-snapshot
Polypharmacology: The Rise of Multitarget Drugs over Combination Therapies
inferredcites →https://doi.org/10.4155/fmc.14.7openalex-snapshot
Potential Strategies for Increasing Drug-Discovery Productivity
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.1002/9783527824014.ch3openalex-snapshot
Principles and Methods of the Pharmaceutical Drug Discovery Process – From Idea over Target to a Development Candidate
inferred← citeshttps://doi.org/10.1002/cmdc.202100710openalex-snapshot
Promoting GAINs (Give Attention to Limitations in Assays) over PAINs Alerts: no PAINS, more GAINs
inferred← citeshttps://doi.org/10.1002/cmdc.202500199openalex-snapshot
Letting Go of Pains and Other Dogmas
inferred← citeshttps://doi.org/10.1016/j.pbiomolbio.2021.02.004openalex-snapshot
An effective human uracil-DNA glycosylase inhibitor targets the open pre-catalytic active site conformation
inferred← citeshttps://doi.org/10.1016/j.phymed.2022.154580openalex-snapshot
Flavonoids and saponins: What have we got or missed?
inferred← citeshttps://doi.org/10.1021/acs.jcim.6b00465openalex-snapshot
Phantom PAINS: Problems with the Utility of Alerts for P an- A ssay IN terference Compound S
inferred← citeshttps://doi.org/10.1021/acs.jcim.8b00385openalex-snapshot
Exploring Activity Profiles of PAINS and Their Structural Context in Target–Ligand Complexes
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.0c00435openalex-snapshot
Discovery and Structure Relationships of Salicylanilide Derivatives as Potent, Non-acidic P2X1 Receptor Antagonists
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.0c00523openalex-snapshot
High-Throughput Screening for the Discovery of Enzyme Inhibitors
inferred← citeshttps://doi.org/10.1038/s41570-024-00593-3openalex-snapshot
Tackling assay interference associated with small molecules
inferred← citeshttps://doi.org/10.1039/d3np00007aopenalex-snapshot
Natural products from plants targeting key enzymes for the future development of antidiabetic agents
inferred← citeshttps://doi.org/10.1080/17460441.2020.1751117openalex-snapshot
The emerging role of computational design in peptide macrocycle drug discovery
inferred← citeshttps://doi.org/10.1111/bph.14876openalex-snapshot
Enriching cancer pharmacology with drugs of marine origin
inferred← citeshttps://doi.org/10.1371/journal.ppat.1007038openalex-snapshot
Biology must develop herd immunity against bad-actor molecules
inferred← citeshttps://doi.org/10.1556/650.2020.31703openalex-snapshot
Több támadáspontú gyógyszerek: múlt, jelen és jövő
inferred← citeshttps://doi.org/10.17615/bs3n-4f22openalex-snapshot
PREDICTIVE CHEMINFORMATICS ANALYSIS OF DIVERSE CHEMOGENOMICS DATA SOURCES: APPLICATIONS TO DRUG DISCOVERY, ASSAY INTERFERENCE, AND TEXT MINING
inferred← citeshttps://doi.org/10.3390/cancers12061504openalex-snapshot
Oncolytic Adenoviruses: Strategies for Improved Targeting and Specificity
inferred← citeshttps://doi.org/10.3390/chemistry4020019openalex-snapshot
Recent Advances in Influenza, HIV and SARS-CoV-2 Infection Prevention and Drug Treatment—The Need for Precision Medicine
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.